We are live on ! Find out more
FLNA

Filana Therapeutics

62 hedge funds and large institutions have $115M invested in Filana Therapeutics in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

289% more call options, than puts

Call options by funds: $447K | Put options by funds: $115K

72% more capital invested

Capital invested by funds: $67.2M → $115M (+$48.2M)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

2% more funds holding

Funds holding: 6162 (+1)

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

Holders
62
Holders Change
+1
Holders Change %
+1.64%
% of All Funds
1.8%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
17
Increased
18
Reduced
18
Closed
16
Calls
$447K
Puts
$115K
Net Calls
+$332K
Net Calls Change
+$282K
Name Holding Trade Value Shares
Change
Change in
Stake
MCM
26
Munder Capital Management
Michigan
$620K
TA
27
Teton Advisors
New York
$539K -$7.2K -271 -2%
BFA
28
BlackRock Fund Advisors
California
$468K -$1.87M -70,600 -84%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$462K
CCMU
30
Cheyne Capital Management (UK)
United Kingdom
$451K +$352K +13,243 New
Northern Trust
31
Northern Trust
Illinois
$445K +$7.12K +268 +2%
BA
32
BlackRock Advisors
Delaware
$401K -$235K -8,848 -43%
GS
33
Gagnon Securities
New York
$339K +$16.9K +635 +7%
ZIM
34
Zacks Investment Management
Illinois
$337K +$263K +9,891 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$265K -$239 -9 -0.1%
PCM
36
Palisade Capital Management
New Jersey
$243K +$37.9K +1,429 +25%
Millennium Management
37
Millennium Management
New York
$189K +$147K +5,547 New
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$185K -$17.6K -662 -11%
PA
39
Perceptive Advisors
New York
$172K +$135K +5,072 New
Two Sigma Investments
40
Two Sigma Investments
New York
$143K +$112K +4,214 New
State Street
41
State Street
Massachusetts
$135K -$37.6K -1,415 -26%
Citadel Advisors
42
Citadel Advisors
Florida
$121K -$240K -9,039 -72%
DekaBank Deutsche Girozentrale
43
DekaBank Deutsche Girozentrale
Germany
$119K +$1.89K +71 +2%
JP Morgan Chase
44
JP Morgan Chase
New York
$116K -$478 -18 -0.5%
LMF
45
LMR Master Fund
Cayman Islands
$109K +$85.2K +3,209 New
Morgan Stanley
46
Morgan Stanley
New York
$97K -$10.9K -409 -13%
CAM
47
ClariVest Asset Management
California
$97K +$75.8K +2,853 New
Charles Schwab
48
Charles Schwab
California
$91K
Connor, Clark & Lunn Investment Management (CC&L)
49
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$75K +$55.4K +2,086 New
SIM
50
Spark Investment Management
New York
$67K +$52.7K +1,986 New

FLNA Hedge Fund Activity: Q4 2013 in Review

62 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2013, worth a combined $115M — up 72% from $67.2M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new FLNA positions and 16 closed out — a net gain of 1 holder — while 18 added to existing stakes and 18 trimmed.

The largest buyer was Sophrosyne Capital, adding an estimated $3.22M. The largest seller was BVF Inc, exiting entirely with an estimated $6.41M sold.

  • 62 institutional investors held Filana Therapeutics (FLNA) as of Q4 2013, up from 61 in Q3 2013.
  • Funds reported $115M of Filana Therapeutics stock for Q4 2013, up 72% quarter-over-quarter.
  • 17 funds opened new Filana Therapeutics positions in Q4 2013 and 16 closed out, a net change of +1 holder.
  • The largest Filana Therapeutics buyer in Q4 2013 was Sophrosyne Capital, an estimated $3.22M added.
  • The largest Filana Therapeutics seller in Q4 2013 was BVF Inc, an estimated $6.41M sold.

Based on aggregated 13F filings for Q4 2013.